Literature DB >> 16282306

Amebic colitis in asymptomatic subjects with positive fecal occult blood test results: clinical features different from symptomatic cases.

Makoto Okamoto1, Takao Kawabe, Ken Ohata, Gouichi Togo, Tetsuya Hada, Tetsurou Katamoto, Masataka Tanno, Masayuki Matsumura, Yutaka Yamaji, Hirotsugu Watabe, Tsuneo Ikenoue, Haruhiko Yoshida, Masao Omata.   

Abstract

Amebiasis is a common parasitic infectious disease in developing countries. In developed countries, it is occasionally encountered in travelers to the tropics and in homosexual males. During the past eight years, we detected four cases of amebic colitis among 5,193 subjects who underwent colonoscopy because of positive fecal occult blood test results in a mass screening. All four cases did not have any abdominal symptoms. Ulcerative lesions were observed only in the cecum and ascending colon; another portion of the colon and rectum appeared normal. We may encounter amebic colitis during colonoscopic examination even in subjects who are asymptomatic.

Entities:  

Mesh:

Year:  2005        PMID: 16282306

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  12 in total

1.  An Exploratory Analysis of Fecal Immunochemical Test Performance for Colorectal Cancer Screening in Nigeria.

Authors:  Gregory C Knapp; Avinash Sharma; Bolatito Olopade; Olusegun I Alatise; Olalekan Olasehinde; Olujide O Arije; Philip E Castle; T Peter Kingham
Journal:  World J Surg       Date:  2019-11       Impact factor: 3.352

2.  Asymptomatic intestinal amebiasis in Japanese HIV-1-infected individuals.

Authors:  Koji Watanabe; Naoyoshi Nagata; Katsunori Sekine; Kazuhiro Watanabe; Toru Igari; Junko Tanuma; Yoshimi Kikuchi; Shinichi Oka; Hiroyuki Gatanaga
Journal:  Am J Trop Med Hyg       Date:  2014-07-21       Impact factor: 2.345

3.  Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions.

Authors:  Marc Tänzer; Benjamin Balluff; Jürgen Distler; Kari Hale; Andreas Leodolter; Christoph Röcken; Bela Molnar; Roland Schmid; Catherine Lofton-Day; Tibor Schuster; Matthias P A Ebert
Journal:  PLoS One       Date:  2010-02-04       Impact factor: 3.240

4.  Fecal occult blood test and gastrointestinal parasitic infection.

Authors:  Majed H Wakid
Journal:  J Parasitol Res       Date:  2010-07-26

5.  Epidemiology of Domestically Acquired Amebiasis in Japan, 2000-2013.

Authors:  Masahiro Ishikane; Yuzo Arima; Atsuhiro Kanayama; Takuri Takahashi; Takuya Yamagishi; Yuichiro Yahata; Tamano Matsui; Tomimasa Sunagawa; Tomoyoshi Nozaki; Kazunori Oishi
Journal:  Am J Trop Med Hyg       Date:  2016-03-14       Impact factor: 2.345

6.  Amoebic toxic colitis: analysis of factors related to mortality.

Authors:  Fátima Ortiz-Castillo; Luis Enrique Salinas-Aragón; Martín Sánchez-Aguilar; J Humberto Tapia-Pérez; Martín Sánchez-Reyna; Mauricio Pierdant-Pérez; José Juan Sánchez-Rodríguez; Juan Francisco Hernández-Sierra
Journal:  Pathog Glob Health       Date:  2012-08       Impact factor: 2.894

7.  Risk factors for intestinal invasive amebiasis in Japan, 2003-2009.

Authors:  Naoyoshi Nagata; Takuro Shimbo; Junichi Akiyama; Ryo Nakashima; So Nishimura; Tomoyuki Yada; Koji Watanabe; Shinichi Oka; Naomi Uemura
Journal:  Emerg Infect Dis       Date:  2012-05       Impact factor: 6.883

8.  Antiamoebic drugs for treating amoebic colitis.

Authors:  Maria Liza M Gonzales; Leonila F Dans; Juliet Sio-Aguilar
Journal:  Cochrane Database Syst Rev       Date:  2019-01-09

9.  Positive fecal occult blood test as a diagnostic cue for Schistosoma mansoni infection in a developed country.

Authors:  Itaru Nakamura; Kenji Yagi; Takashi Kumagai; Nobuo Ohta
Journal:  IDCases       Date:  2017-10-20

10.  Fecal occult blood and fecal calprotectin as point-of-care markers of intestinal morbidity in Ugandan children with Schistosoma mansoni infection.

Authors:  Amaya L Bustinduy; José C Sousa-Figueiredo; Moses Adriko; Martha Betson; Alan Fenwick; Narcis Kabatereine; J Russell Stothard
Journal:  PLoS Negl Trop Dis       Date:  2013-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.